grífols

Catalan drugmaker accused of 'serious violation' for providing inaccurate or misleading financial information

CNMV believes Catalan company's debt is reflected correctly despite deficiencies

Catalan pharmaceutical giant bounces back despite recent short-seller attack

Catalan drugmaker accounts are being examined and Gotham's actions questioned

Thomas Glanzmann says claims in short seller's report are 'false'

Catalan company Grífols develops potential supplement to vaccine rollout with first results to be known in spring

Catalan multinational will collect plasma from recovering covid-19 patients with aim of producing hyperimmune antibodies

Grífols claims clinical trial suggests reduction in disease's progression 

World's major supplier of plasma products aims to fund new plants, while consolidating its place in Chinese market

Revenue up to €4.4bn; figures slightly better than previous year

Catalan pharmaceutical multinational’s revenue grows to 1,023 million euros in first three months of year

Pharmaceutical company Grifols to join forces with AIDS research institute IrisCaixa to further investigation into treatments for disease

Although the company has “no plans” to leave Catalonia, if politics affects business it will have to take "necessary measures"